Enjoy complimentary customisation on priority with our Enterprise License!
The Global Biomarkers Market size is estimated to grow at a CAGR of 13.05% between 2022 and 2027. The market size is forecasted to increase by USD 56,267.85 million. The growth of the market depends on several factors, including the increasing prevalence of heart diseases, the growing advances in genomics and proteomics, and the growing focus on the development of biomarker-based diagnostic methods.
This biomarkers market report extensively covers market segmentation by type (safety, efficacy, and validation), application (drug discovery and development, diagnostics, and personalized medicine), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges.
To learn more about this report, Request Free Sample
Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing prevalence of heart diseases is notably driving market growth. The increase in the use of biomarkers for patients with heart disease has grown over the past few years. Natriuretic peptides are the most popular biomarkers and aid in the identification of patients with heart failure. Heart disease is a leading cause of death. The rise in heart diseases will drive the demand for biomarkers. For instance, in 2021, according to the Centers for Disease Control and Prevention (CDC), approximately 6.5 million people aged 40 years and above in the US had peripheral arterial disease (PAD). Low awareness, especially in the growing economies of Asia, is the main primary reason for the high incidence of the disease.
Smoking, high prevalence of cardiac arrhythmias, atherosclerosis, diabetes, and high cholesterol are other factors that indirectly contribute to the prevalence of heart disease. The prevalence of CVDs is increasing owing to the growth of risk factors, such as diabetes, hypertension, smoking, and obesity. Such factors are expected to increase the demand for cardiac biomarkers, which will further fuel the growth of the global biomarkers market during the forecast period.
The growing number of research and development programs and new product launches is a key trend shaping the market. The expansion of the global biomarkers market is expected to be fueled by the rising number of R&D programs and new product launches. For instance, according to an article from the British Journal of Cancer on October 3, 2022, using the BC-116 biomarker panel as a test to detect primary bladder cancer is beneficial. In February 2022, the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium announced a new project called Neurofilament as a Fluid Biomarker of Neurodegeneration in Familial Frontotemporal Degeneration (FTD) to determine the most effective blood tests for measuring a protein essential for the early detection of rare neurodegenerative diseases.
In October 2021, DarwinHealth and Prelude Therapeutics started to work together to create novel biomarkers for numerous oncology candidates. The revenue share of the cardiovascular diseases segment was the second largest in 2022. Thus, the growing number of R&D programs and new product launches are expected to boost the growth of the global biomarkers market during the forecast period.
The high cost associated with the development and validation of biomarker tests and infrastructure is challenging market growth. Cost and infrastructure challenges can impact the development, implementation, and accessibility of biomarker-based diagnostics and therapies. The development and validation of biomarker tests require high investments in infrastructure, equipment, and skilled personnel. However, such investments are unaffordable for smaller research institutions or healthcare facilities with limited resources, which hinders their ability to participate in biomarker research or offer biomarker-based tests.
The cost associated with biomarker discovery, validation, and commercialization can be significantly high. The costs of developing and manufacturing biomarker-based diagnostic kits or companion diagnostics are also high, which are ultimately passed on to end-users such as patients, healthcare providers, and payers. Biomarker research and implementation require access to specialized laboratory facilities, advanced imaging equipment, molecular analysis tools, and bioinformatics resources. However, in regions or healthcare systems with limited infrastructure or inadequate technological capabilities, the development and implementation of biomarker-based diagnostics may be hindered. These factors will support market growth during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Biomarkers Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abbott Laboratories - The company offers biomarkers such as proprietary assays for cardiovascular health, infectious diseases, and oncology, providing advanced diagnostic solutions for personalized patient care and precision medicine. Under the Established Pharmaceuticals Products segment, the company manufactures branded generic pharmaceuticals for established and emerging markets.
The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth by the safety segment will be significant during the forecast period. Safety biomarkers have the capability to recognize or anticipate negative drug or exposure effects.
Get a glance at the market contribution of various segments View the PDF Sample
The safety segment was valued at USD 21,266.61 million in 2017 and continued to grow until 2021. Regular monitoring of biomarkers is necessary to identify and control any potential toxicity of drugs. A safety biomarker should alert before any clinical signs or irreversible harm is done. Effects on biomarkers can sometimes lead to rare but potentially harmful toxicity. Biomarkers can be used to identify patients for whom specific therapies should not be started due to significant safety risks. Thus, the various benefits of safety biomarkers are expected to increase their use, which will further drive the growth of the safety biomarkers segment in the global biomarkers market during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The US accounted for the largest market share in North America. The number of drug labels with molecular biomarker information has increased over the past ten years. Moreover, the demand for efficient and precise biomarkers has increased due to the rising prevalence of chronic diseases in the US. The biomarkers market in the region is anticipated to grow significantly during the forecast period due to the critical role played by biomarkers in the early diagnosis and treatment of chronic diseases. Governments are also focusing on the investigation and creation of biomarkers for various uncommon neurodegenerative illnesses. The demand for biomarkers is expected to increase during the forecast period, as they have numerous applications in the detection and treatment of cancer. Such factors will drive the growth of the biomarkers market in North America during the forecast period.
The outbreak of COVID-19 in 2020 had a mixed impact on the biomarkers market in North America. The pandemic caused disruptions in R&D activities, including biomarker discovery and validation studies, as many research institutions and laboratories had to temporarily shut down or limit their operations. However, the pandemic also created a surge in demand for biomarkers for the diagnosis, prognosis, and monitoring of COVID-19. The increased demand for COVID-19-related biomarkers partially offset the negative impact on the overall biomarkers market in 2020. In addition, lockdown restrictions were lifted in the second half of 2020 owing to rapid vaccination drives across the region. This led to the resumption of R&D activities, which helped the market recover in the first half of 2021. Thus, the growing number of clinical trials and R&D activities related to biomarkers will drive the growth of the biomarkers market in North America during the forecast period.
The biomarkers market report forecasts market growth by revenue at global, regional, & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Biomarkers Market Scope |
|
Report Coverage |
Details |
Page number |
157 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 13.05% |
Market growth 2023-2027 |
USD 56,267.85 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
12.53 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 38% |
Key countries |
US, UK, Germany, China, and Japan |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, Abcam plc, Agilent Technologies Inc., Becton Dickinson and Co., BG Medicine Inc., Bio Techne Corp., CENTOGENE NV, Charles River Laboratories International Inc., DiaSorin Spa, EKF Diagnostics Holdings Plc, Eurofins Scientific SE, F. Hoffmann La Roche Ltd., General Electric Co., Merck KGaA, Meso Scale Diagnostics LLC, Nexus Dx Inc., QIAGEN NV, Quest Diagnostics Inc., Siemens AG, and Thermo Fisher Scientific Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.